Drug Information

Drug General Information
Drug ID
D0Q8LL
Former ID
DIB004944
Drug Name
SYL-040012
Synonyms
SYL-0012; Beta 2 adrenoceptor-targeting siRNA (ocular hypertension), Sylentis
Drug Type
siRNA drug
Indication Ocular hypertension [ICD9: 365.04; ICD10:H40.0] Phase 2 [524931]
Company
Sylentis Sau
Target and Pathway
Target(s) mRNA of Beta 2 adrenoceptor Target Info [532475]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Adrenergic signaling in cardiomyocytes
Salivary secretion
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta2 adrenergic receptor signaling pathway
Pathway Interaction Database Arf6 trafficking events
Arf6 signaling events
Reactome Adrenoceptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 524931ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma. U.S. National Institutes of Health.
Ref 532475In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.